Novoprotein Scientific Says AI-Enabling High-Throughput Wet Lab and Data Package Services Still in Early Market Development Stage

Stock News
Oct 07

Novoprotein Scientific Inc. (688137.SH) has issued a risk warning announcement regarding severe abnormal fluctuations in its stock trading, according to the company.

The company disclosed that revenue from RNA vaccine drug-related products in 2025 accounted for 11.38% of total product revenue, representing a relatively low proportion.

Its AI-enabling high-throughput wet lab and data package services remain in the early stage of market development, with related business revenue accounting for less than 2% of the company's total operating revenue as of the first half of 2026.

Given that the application of AI in the pharmaceutical R&D industry is still in its infancy, there are risks including rapid technological iteration, lengthy industry validation cycles, and significant difficulties in commercial implementation.

The company's future revenue and profit realization from related businesses face substantial uncertainty.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10